Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 2L | Second line of therapy |
| 5-FU | 5-fluorouracil |
| 7MM | Seven major markets (United States, EU4, United Kingdom, and Japan) |
| ACC | Adenoid cystic carcinoma |
| ACC-I, ACC-1 | Adenoid cystic carcinoma molecular subtype I (aggressive subtype; also written ACC I and ACC type 1) |
| ACC-II | Adenoid cystic carcinoma molecular subtype II (indolent subtype; also written ACC II) |
| AcCC | Acinic cell carcinoma |
| ACCHN | Adenoid cystic carcinoma of the head and neck |
| ACCRF | Adenoid Cystic Carcinoma Research Foundation |
| ADA | Antidrug antibody |
| ADC | Antibody-drug conjugate |
| AdCC | Adenoid cystic carcinoma |
| ADLT | Advanced diagnostic laboratory test |
| AF | Auristatin F |
| AF-HPA | Auristatin F hydroxypropylamide (also written auristatin F-HPA) |
| AHFS | American Hospital Formulary Service |
| ALP | Alkaline phosphatase |
| ALT | Alanine aminotransferase |
| ARID1B | AT-rich interaction domain 1B |
| ASCO | American Society of Clinical Oncology |
| AST | Aspartate aminotransferase |
| ATC | Anatomical Therapeutic Chemical classification |
| AUC | Area under the concentration-time curve |
| AUROC | Area under the receiver operating characteristic curve |
| AXL | AXL receptor tyrosine kinase |
| B7-H4 | B7 homolog 4 (encoded by VTCN1) |
| BC | Breast cancer |
| BIRC | Blinded independent review committee |
| BOR | Best overall response |
| C-T | Cribriform-tubular (histologic type) |
| C12 | Carbon ion (radiotherapy) |
| CAGR | Compound annual growth rate |
| CAP | Cisplatin, doxorubicin (Adriamycin), and cyclophosphamide |
| CD 117 | Cluster of differentiation 117 (c-kit) |
| CDT | Central Daylight Time |
| CEA | Cost-effectiveness analysis |
| cGMP | Current good manufacturing practice |
| ChT | Chemotherapy |
| CI | Confidence interval |
| Cmax | Maximum observed plasma concentration |
| CMO | Contract manufacturing organization |
| CMS | Centers for Medicare & Medicaid Services |
| CNS | Central nervous system |
| cORR | Confirmed objective response rate |
| COST | Comprehensive Score for Financial Toxicity |
| CR | Complete response |
| CREBBP | CREB-binding protein |
| CT | Computed tomography |
| CVR | Contingent value right |
| D1+8 | Days 1 and 8 |
| DAR | Drug-to-antibody ratio |
| DCR | Disease control rate |
| DES | Dose escalation |
| DF | Dolaflexin |
| DFI | Disease-free interval |
| DFS | Disease-free survival |
| DLT | Dose-limiting toxicity |
| DNA | Deoxyribonucleic acid |
| DOR, DoR | Duration of response |
| DRR | Dose reduction rate |
| DS | Dolasynthen |
| DSS | Disease-specific survival |
| EC | Endometrial cancer |
| ECOG | Eastern Cooperative Oncology Group |
| EFS | Event-free survival |
| EGFR | Epidermal growth factor receptor |
| EMA | European Medicines Agency |
| Emi-Le | Emiltatug ledadotin |
| EQ-5D-5L | EuroQol 5-dimension 5-level questionnaire |
| EQV | EQ-5D value |
| ESMO | European Society for Medical Oncology |
| EU4 | France, Germany, Italy, and Spain |
| EURACAN | European Reference Network on Rare Adult Solid Cancers |
| EXP | Dose expansion |
| FDA | US Food and Drug Administration |
| FIH | First-in-human |
| FISH | Fluorescence in situ hybridization |
| G3, G4 | Grade 3, grade 4 |
| GLOBOCAN | Global Cancer Incidence, Mortality and Prevalence database |
| HER2, HER2/neu | Human epidermal growth factor receptor 2 |
| HGT | High-grade transformation |
| HNACC | Head and neck adenoid cystic carcinoma |
| HR | Hazard ratio |
| HR+ | Hormone receptor-positive |
| HRQoL | Health-related quality of life |
| ICER | Incremental cost-effectiveness ratio |
| ID | Identifier |
| IgG1 | Immunoglobulin G1 |
| IHC | Immunohistochemistry |
| IMC | Imaging mass cytometry |
| IMRT | Intensity-modulated radiotherapy |
| INN | International nonproprietary name |
| ISH | In situ hybridization |
| IV | Intravenous |
| KDM6A | Lysine demethylase 6A |
| KMT2C, MLL3 | Lysine methyltransferase 2C (mixed-lineage leukemia 3) |
| LDH | Lactate dehydrogenase |
| LS | Large signals (percentage of tumor cells with large MYB RNA in situ hybridization signals) |
| LY | Life-year |
| M1 | Distant metastasis present at diagnosis (TNM category) |
| MDM2 | Mouse double minute 2 homolog |
| MET | MET proto-oncogene, receptor tyrosine kinase |
| miR | MicroRNA |
| MMAE | Monomethyl auristatin E |
| Mo-Rez | Mocertatug rezetecan |
| mOS | Median overall survival |
| MRI | Magnetic resonance imaging |
| mRNA | Messenger RNA |
| MSI-H | Microsatellite instability-high |
| MTD | Maximum tolerated dose |
| MYB | MYB proto-oncogene, transcription factor |
| MYBL1 | MYB proto-oncogene like 1 |
| MYC, c-Myc | MYC proto-oncogene, bHLH transcription factor |
| N/A | Not applicable |
| NAb | Neutralizing antibody |
| NCCN | National Comprehensive Cancer Network |
| NFIB | Nuclear factor I B |
| NGS | Next-generation sequencing |
| NICD1 | NOTCH1 intracellular domain |
| NOTCH1 to NOTCH4 | Notch receptors 1 to 4 |
| NR | Not reached |
| OC/OP/SG | Oral cavity, oropharyngeal, and salivary gland cancers |
| ORR | Objective response rate |
| OS | Overall survival |
| P&T | Pharmacy and therapeutics |
| P-Sam | Puxitatug samrotecan |
| p63 | Tumor protein p63 (encoded by TP63) |
| PD | Progressive disease |
| PD-1 | Programmed cell death protein 1 |
| PDX | Patient-derived xenograft |
| PFS | Progression-free survival |
| PgP | P-glycoprotein |
| PI3K | Phosphoinositide 3-kinase |
| PK | Pharmacokinetics |
| PM | Pulmonary metastasis |
| PM-LT | Pulmonary metastasis-directed local therapy |
| PR | Partial response |
| PRMT5 | Protein arginine methyltransferase 5 |
| PROC | Platinum-resistant ovarian cancer |
| pts | Patients |
| Q3W | Every 3 weeks |
| Q4W | Every 4 weeks |
| QALY | Quality-adjusted life-year |
| QoL, QOL | Quality of life |
| R/M | Recurrent or metastatic |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| REFCOR | French Network of Rare Head and Neck Tumors (Réseau d'Expertise Français sur les Cancers ORL Rares) |
| REMS | Risk evaluation and mitigation strategy |
| RNA | Ribonucleic acid |
| RNA-seq | RNA sequencing |
| RP2D | Recommended phase 2 dose |
| RPPA | Reverse-phase protein array |
| RR | Response rate |
| RT | Radiotherapy |
| RT-PCR | Reverse transcription polymerase chain reaction |
| S | Solid (histologic type) |
| SBRT | Stereotactic body radiation therapy |
| SD | Stable disease |
| SEER | Surveillance, Epidemiology, and End Results program |
| SGC | Salivary gland cancer |
| SGM | Salivary gland malignancy |
| SMARCA2 | SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 2 |
| TEAE | Treatment-emergent adverse event |
| TKI | Tyrosine kinase inhibitor |
| TMB | Tumor mutational burden |
| TME | Tumor microenvironment |
| TNBC | Triple-negative breast cancer |
| Top1i | Topoisomerase I inhibitor |
| topo-1 | Topoisomerase-1 |
| TP53 | Tumor protein p53 gene |
| TP63 | Tumor protein p63 gene |
| TPS | Tumor proportion score |
| TRAE | Treatment-related adverse event |
| TROP2 | Trophoblast cell-surface antigen 2 |
| TTM | Time to metastasis |
| TTP | Time to progression |
| UK | United Kingdom |
| uPR | Unconfirmed partial response |
| UpRi | Upifitamab rilsodotin |
| US, U.S. | United States |
| USD, US$ | United States dollars |
| UTR | Untranslated region |
| VEGFR | Vascular endothelial growth factor receptor |
| VEGFRi | VEGFR inhibitor |
| VTCN1 | V-set domain-containing T-cell activation inhibitor 1 |
| VWAP | Volume-weighted average price |
| WHO | World Health Organization |
| WTP | Willingness to pay |